Renowned Experts Dr. Robert Schreiber and Dr. Garry Nolan Join as Inaugural Members
St. Louis, MO — September 29th, 2025 —
Leinco Technologies, a leader in antibody and protein development, is pleased to announce the formation of its Scientific Advisory Board (SAB). The newly established board will provide strategic guidance on scientific initiatives, research priorities, and emerging technologies, further strengthening Leinco’s commitment to advancing biomedical innovation.
As part of this initiative, Leinco welcomes two distinguished scientists, Dr. Robert Schreiber and Dr. Garry Nolan as inaugural members of the SAB. Their expertise will play a vital role in shaping Leinco’s research and development strategies.
Dr. Robert Schreiber is a pioneering immunologist and professor at Washington University in St. Louis. He is renowned for his groundbreaking work in cancer immunotherapy and tumor immunology, particularly for coining the concept of “cancer immunoediting.” His insights will be invaluable to Leinco’s antibody and protein development efforts for the scientific advisory board (SAB).
Dr. Garry Nolan is a distinguished immunologist and cell biologist at Stanford University. He’s a pioneer in single-cell analysis and computational biology, which has revolutionized the field. Dr. Nolan’s expertise in systems immunology and cancer research will be crucial for Leinco’s scientific advisory board, offering valuable insights for our next-generation diagnostic and therapeutic innovations.
“The formation of our Scientific Advisory Board represents a significant step in strengthening our scientific leadership,” said William Leinert Sr., President and CEO of Leinco Technologies. “Dr. Schreiber and Dr. Nolan are among the foremost experts in their fields, and their guidance will be instrumental in driving forward Leinco’s mission to develop cutting-edge solutions for global health challenges.”
The SAB will work closely with Leinco’s leadership and R&D teams to ensure the company remains at the forefront of scientific advancements. This initiative aligns with Leinco’s commitment to translating research into practical applications that improve patient outcomes worldwide.
For more information about Leinco Technologies and its Scientific Advisory Board, please visit www.leinco.com.
About Leinco Technologies Inc.
Leinco Technologies specializes in the research, development, and production of high-quality antibodies and proteins for diagnostics, therapeutics, and research. With a strong commitment to innovation and collaboration, Leinco strives to provide solutions that address critical global health challenges.
